Clinical Trial: Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)

U.S., Jan. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07317934) titled 'Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)' on Dec. 19, 2025.

Brief Summary: This is a Phase III, randomized, open-label, active-controlled study to evaluate the efficacy and safety of subretinal injection of LX102 in participants with neovascular age-related macular degeneration. The study will evaluate a single subretinal injection of LX102 compared to an active comparator. The primary endpoint of this study is the mean change from D0 in BCVA based on an average at weeks 40 and 48.

Study Start Date: Jan., 2026

Study Type: INTERVENTIONAL

Condition: Neo...